Sign in
CompletedNo phase

Hypofractionated Radiosurgery to Treat Residual/Recurrent Non Secreting Pituitary Adenoma (HYPOADENO)

Key facts

Who runs it
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
25 people enrolled
Started
14 Sept 2020
Ended
20 May 2025
Type of study
Interventional
Treatments tested
  • hypofractionated radiosurgery
Record updated
30 March 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Residual or progressive non secreting pituitary adenoma
  • Exclusion of other treatment approach (second surgery, wait and scan; suppressive therapy) by a multidisciplinary team
  • Age ≥ 18 years; KPS ≥ 70
  • Written privacy consent
  • Ability to give informed consent

Who cannot take part

  • Previous cranial irradiation
  • Diagnosis of secreting adenoma
  • pregnancy status
  • unable to undergo MRI or CT scans
  • unable to give informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Single session stereotactic radiosurgery (SRS) is commonly used for patients with non-functioning adenomas. However the SRS can be limited by the proximity of the tumor with the surrounding critical structures (i.e., the optic chiasm).

Read full original descriptionShow less

The goal of the present prospective phase II trial is to investigate early and early delayed toxicity for cranial nerves and pituitary function after hypofractionated stereotactic radiotherapy/multisession radiosurgery (hSFRT/mSRS) in residual/ recurrent non secreting pituitary adenomas. Secondary end points are late toxicity and tumour growth local control.

All the enrolled patients will undergo radiosurgical treatment with a hypofractionation schedule Following radiotherapy, follow-up will be scheduled every 6 months during the first year post-radiosurgery and then annually, with the same tests.

The baseline examination and the follow-up assessment will include magnetic resonance imaging (MRI), full blood counts and blood chemistry tests, neuro-ophtalmology evaluation, physical and psychological examination that included a quality-of-life (EORTC Quol 30; BN 20) and a Hospital Anxiety and Depression Scale (HADS).

The group in the trial

  • RadiosurgeryTreatment being tested

    Patients suffering from residual/recurrent non functioning pituitary adenoma wil undergo to hypofractionated radiosurgery

    Treatment: hypofractionated radiosurgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY/MULTISESSION RADIOSURGERY (HSFRT/MSRS) IN RESIDUAL/ RECURRENT NON SECRETING PITUITARY ADENOMAS AN EXPLORATORY STUDY
Record updated
30 March 2026